University Hospital Southampton NHS Foundation Trust

Running trials

• Not yet recruiting

  Remote Monitoring and Optimization of Heart Failure Therapy

  NCT07622472· Zoll Medical Corporation· Source

• Recruiting

  Comparing Advanced Technologies to Standard Testing for the Diagnosis of Airway Disease in Hospital and Community Settings

  NCT07798596· University Hospital Southampton NHS Foundation Trust· Source

• Recruiting

  Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer

  NCT07831902· Phase 3· University College, London· Source

• Recruiting

  A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  NCT07226843· Phase 1· Eli Lilly and Company· Source

• Recruiting

  A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  NCT07489495· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A 2-part Phase 1/2 Open-label Trial on ODM-212

  NCT07563738· Phase 1/2· Orion Corporation, Orion Pharma· Source

• Recruiting

  IMMUNO-FIT Observational Study

  NCT07354971· University Hospital Southampton NHS Foundation Trust· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Pilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06488638· University Hospital Southampton NHS Foundation Trust· Source

• Recruiting

  Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

  NCT06875128· Phase 2· Delcath Systems Inc.· Source

• Recruiting

  Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

  NCT07230288· Phase 2· AbbVie· Source

• Active, not recruiting

  Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

  NCT07087054· Phase 3· Crinetics Pharmaceuticals Inc.· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  NCT06659445· Phase 2· ONL Therapeutics· Source

• Recruiting

  To Identify if a COPD Self-management App Can Safety and Appropriately Identify When Patients Are Not on the Best Medication Plan for Their COPD Symptoms and Support Their COPD Management.

  NCT07797985· Phase 1· University of Southampton· Source

• Recruiting

  Evaluation of Seismocardiography(SCG) for Assessing Fitness and Predicting Outcomes in Oesophageal Cancer Surgery

  NCT07159711· Guy's and St Thomas' NHS Foundation Trust· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  Validation Of A Parent Administered Symptom Score For Unsettled Infants (Every Baby is UnIQue)

  NCT07121062· University Hospital Southampton NHS Foundation Trust· Source

• Recruiting

  Improving Quality of Life for Teenagers With Asthma

  NCT06851715· University Hospital Southampton NHS Foundation Trust· Source

• Recruiting

  A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

  NCT07144137· Complement Therapeutics· Source

• Recruiting

  Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

  NCT05691244· Phase 3· Pharmazz, Inc.· Source

• Recruiting

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· Phase 3· Pfizer· Source

• Active, not recruiting

  A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06736990· Phase 2· Calluna Pharma AS· Source

• Recruiting

  A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial

  NCT06786234· Phase 2· Step Pharma, SAS· Source

• Recruiting

  Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

  NCT06697301· Phase 2/3· Eikon Therapeutics· Source

• Recruiting

  Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns

  NCT06985706· Phase 3· Belfast Health and Social Care Trust· Source

• Active, not recruiting

  FARAPULSE Workflow Assessment Registry

  NCT06656884· Boston Scientific Corporation· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  The Dragon PLC Trial (DRAGON-PLC)

  NCT06914648· Maastricht University· Source

• Active, not recruiting

  REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure

  NCT06557798· The Leeds Teaching Hospitals NHS Trust· Source

• Recruiting

  A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease

  NCT07363044· Alimentiv Inc.· Source

• Recruiting

  Supported Rescue Packs Post-discharge in Chronic Obstructive Pulmonary Disease

  NCT06347536· Phase 3· Guy's and St Thomas' NHS Foundation Trust· Source

• Recruiting

  Risk Characterization of Non-culprit Vessels in Patients Undergoing Primary PCI for ST-elevation MI in Multivessel Disease

  NCT06506448· University Hospital Southampton NHS Foundation Trust· Source

• Not yet recruiting

  The U.K. NorthStar Clinical Network

  NCT06711692· University College, London· Source

• Enrolling by invitation

  REAl World Dementia OUTcomes: Observational Study

  NCT07238049· University of Oxford· Source

• Recruiting

  A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

  NCT06547840· Phase 1· Epsilogen Ltd· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

  NCT06461897· Phase 3· AbbVie· Source

• Recruiting

  A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

  NCT06297590· Phase 1· Eli Lilly and Company· Source

• Recruiting

  A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

  NCT06380816· Phase 1/2· Cancer Research UK· Source

• Recruiting

  Understanding the Variation of Modern Endoscopic Ultrasound Use in Patients With Oesophageal Cancer (VALUE)

  NCT06440174· University Hospital Southampton NHS Foundation Trust· Source

• Recruiting

  A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

  NCT06504147· Phase 2· Oncoinvent Solutions AS· Source

• Recruiting

  Multivessel Balloon Occlusion to Investigate Obstructive Coronary Artery Disease and aNgina

  NCT06400290· Imperial College London· Source

• Enrolling by invitation

  Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - SUMMIT (Part 2)

  NCT06682455· University of Southampton· Source

• Recruiting

  Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance)

  NCT06280781· Imperial College London· Source

• Recruiting

  IRONHEART: Intravenous Iron in Non-ischaemic Heart Failure

  NCT06542822· University Hospital Southampton NHS Foundation Trust· Source

• Active, not recruiting

  A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

  NCT06211764· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

  NCT06237335· Phase 2· ReCode Therapeutics· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  NCT06143878· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies

  NCT05789758· Biogen· Source

• Active, not recruiting

  Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06029972· Phase 2· Gilead Sciences· Source

• Recruiting

  The Fourth Left Atrial Appendage Occlusion Study

  NCT05963698· Hamilton Health Sciences Corporation· Source

Showing 50 of 131.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers7 recruiting
• Coronary artery disease6 recruiting
• Prostate cancer5 recruiting
• Stroke5 recruiting
• Heart failure4 recruiting
• Lung cancer4 recruiting
• Macular degeneration4 recruiting
• Colorectal cancer3 recruiting
• COPD3 recruiting
• Diffuse large B-cell lymphoma3 recruiting
• Follicular lymphoma3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Idiopathic pulmonary fibrosis3 recruiting
• Ovarian cancer3 recruiting
• Pancreatic cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Acute myeloid leukaemia2 recruiting
• Alzheimer disease2 recruiting
• Atrial fibrillation2 recruiting
• Bladder cancer2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Endometrial cancer2 recruiting
• Kidney cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Mild cognitive impairment2 recruiting
• Myelodysplastic syndromes2 recruiting
• Peripheral artery disease2 recruiting
• Spinal muscular atrophy2 recruiting
• Asthma1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Crohn's disease1 recruiting
• Diabetic eye disease1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Frontotemporal dementia1 recruiting
• Haemophilia1 recruiting
• Head and neck cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Huntington's disease1 recruiting
• Hyperparathyroidism1 recruiting
• Liver cirrhosis1 recruiting
• Lupus (SLE)1 recruiting
• Mantle cell lymphoma1 recruiting
• Melanoma1 recruiting
• Mesothelioma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Sarcoma1 recruiting

Closed trials

• Completed

  Randomised Comparison of the Octaray and Pentaray Catheters

  NCT05988424· University Hospital Southampton NHS Foundation Trust· Source

• Completed

  Food Quantification Using a Novel, User Friendly Plate Imaging System

  NCT07183449· University of Southampton· Source

• Completed

  OASIS: RetrOspective Analysis on EEGs for Identifying Seizure Susceptibility in paediatrIcs Using biomarkerS

  NCT06546410· Neuronostics Ltd· Source

• Completed

  A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

  NCT06299111· Phase 2· Regeneron Pharmaceuticals· Source

• Completed

  Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma

  NCT06650605· Phase 1· Theragnostics Ltd· Source

• Completed

  Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF

  NCT06468527· Phase 2· Kors van der Ent· Source

• Completed

  A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

  NCT06166056· Phase 1/2· Chiesi Farmaceutici S.p.A.· Source

• Completed

  An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

  NCT06021054· Phase 3· Viridian Therapeutics, Inc.· Source

• Completed

  An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK)

  NCT06126146· AbbVie· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source

• Terminated

  Study of GS-0272 in Participants With Rheumatoid Arthritis

  NCT06031415· Phase 1· Gilead Sciences· Source

• Completed

  Acorai Machine Learning Generalization (MLG) Study

  NCT05835024· Acorai AB· Source

• Completed

  Atrial Fibrillation Driver Study

  NCT05743829· University Hospital Southampton NHS Foundation Trust· Source

• Completed

  NiPPeR Randomised Trial - Child Follow Up Study

  NCT05934422· University of Southampton· Source

• Completed

  A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05507580· Phase 4· AbbVie· Source

• Completed

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

  NCT05551741· Phase 1· Immunobrain Checkpoint· Source

• Completed

  Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

  NCT05797896· Complement Therapeutics· Source

• Completed

  A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).

  NCT05513950· Phase 1· Chiesi Farmaceutici S.p.A.· Source

• Completed

  Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure

  NCT05419115· Phase 2· NHS Greater Glasgow and Clyde· Source

• Completed

  Diagnostic Tools to Establish the Presence and Severity of Peripheral Arterial Disease in People With Diabetes

  NCT05009602· Imperial College London· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Completed

  Bacterial Lysate In Preventing Asthma

  NCT05064631· Phase 2· Queen Mary University of London· Source

• Completed

  A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck

  NCT04830592· Phase 1· Akamis Bio· Source

• Terminated

  A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

  NCT05085366· Phase 3· ModernaTX, Inc.· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Hoffmann-La Roche· Source

• Completed

  Immune Responses to COVID-19 Vaccination in Lymphoma Patients

  NCT04858568· University Hospital Southampton NHS Foundation Trust· Source

• Terminated

  Abiraterone Acetate in Combination With Tildrakizumab

  NCT04458311· Phase 1/2· Institute of Cancer Research, United Kingdom· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

  NCT04428151· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML

  NCT05933070· Phase 1· Inmune Bio, Inc.· Source

• Completed

  Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR

  NCT04295577· Royal Marsden NHS Foundation Trust· Source

• Completed

  Ustekinumab Real World Evidence Study

  NCT07748338· University Hospital Southampton NHS Foundation Trust· Source

• Terminated

  Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

  NCT03696290· Phase 4· University of Dundee· Source

• Recruiting

  A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  NCT04104776· Phase 1/2· Novartis Pharmaceuticals· Source

• Completed

  Paediatric Peri-operative Anxiety: Does the Little Journey App Help?

  NCT03797716· University College, London· Source

• Completed

  Long-Term PF-06651600 for the Treatment of Alopecia Areata

  NCT04006457· Phase 3· Pfizer· Source

• Completed

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· Phase 3· Stemline Therapeutics, Inc.· Source

• Completed

  A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

  NCT03607422· Phase 3· AbbVie· Source

• Completed

  Study to Evaluate CCS1477 in Advanced Tumours

  NCT03568656· Phase 1/2· CellCentric Ltd.· Source

• Completed

  Selinexor, Cyclophosphamide and Prednisone in Myeloma

  NCT06212596· Phase 2· University of Leeds· Source

• Completed

  HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

  NCT03569891· Phase 3· CSL Behring· Source

• Completed

  Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

  NCT03517449· Phase 3· Eisai Inc.· Source

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· Phase 3· Endocyte· Source

• Terminated

  Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5

  NCT03520712· Phase 1/2· BioMarin Pharmaceutical· Source

• Completed

  Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

  NCT03370913· Phase 3· BioMarin Pharmaceutical· Source

• Completed

  A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma

  NCT03307746· Phase 1/2· University Hospital Southampton NHS Foundation Trust· Source

• Completed

  Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

  NCT03040999· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Non-interventional Study to Evaluate Long Term Safety, Prescription Management Patterns of Esmya in a Long Term Setting

  NCT02748460· PregLem SA· Source

• Completed

  A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

  NCT02615691· Phase 3· Baxalta now part of Shire· Source

Showing 50 of 53.

Conditions

Diseases this institution publishes on or runs trials for.

• Asthma62 works · 3 trials
• Fatty liver disease (MASLD/MASH)32 works · 1 trial
• Cystic fibrosis15 works · 3 trials
• Chronic rhinosinusitis with nasal polyps8 works · 0 trials
• Mantle cell lymphoma4 works · 2 trials
• Chronic spontaneous urticaria4 works · 0 trials
• Iron deficiency anaemia4 works · 0 trials